HämostaseologiePub Date : 2023-12-14DOI: 10.1055/s-0043-1777816
{"title":"Potenzielle globale Gerinnungsparameter für Therapiemonitoring unter Emicizumab","authors":"","doi":"10.1055/s-0043-1777816","DOIUrl":"https://doi.org/10.1055/s-0043-1777816","url":null,"abstract":"<p>\u0000<b>Während die Behandlung der genetisch bedingten Gerinnungsstörung Hämophilie A in der Vergangenheit in regelmäßigen intravenösen Faktor-VIII-Infusionen bestand, steht heute mit dem Antikörper Emicizumab eine effektive Alternative zur subkutanen Applikation zur Verfügung. Bisher fehlen allerdings Parameter, mit denen sich das Ausmaß der Gerinnungskorrektur beim einzelnen Patienten verlässlich abbilden lässt. In einer aktuellen Studie kristallisierten sich jetzt zwei globale Gerinnungsparameter heraus, mit denen ein solches Monitoring möglich sein könnte.</b>\u0000</p> ","PeriodicalId":501645,"journal":{"name":"Hämostaseologie","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138680297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HämostaseologiePub Date : 2023-12-14DOI: 10.1055/s-0043-1777817
{"title":"Marker der Akute-Phase-Reaktion könnten Blutungen bei Hämophilie detektieren","authors":"","doi":"10.1055/s-0043-1777817","DOIUrl":"https://doi.org/10.1055/s-0043-1777817","url":null,"abstract":"Bei der Hämophilie A und B werden im Rahmen von akuten Hämorrhagien Entzündungsreaktionen ausgelöst. Sind Gelenke von den Blutungen betroffen, kann hieraus die so genannte hämophile Arthropathie resultieren. In einer aktuellen Studie wurden jetzt Patienten mit Hämophilie im Hinblick auf Marker der Akute-Phase-Reaktion untersucht. Darüber hinaus wurde ein Tiermodell etabliert.","PeriodicalId":501645,"journal":{"name":"Hämostaseologie","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138680700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HämostaseologiePub Date : 2023-12-08DOI: 10.1055/a-2117-4614
Jennifer Gebetsberger, Florian Prüller
{"title":"Classic Light Transmission Platelet Aggregometry: Do We Still Need it?","authors":"Jennifer Gebetsberger, Florian Prüller","doi":"10.1055/a-2117-4614","DOIUrl":"https://doi.org/10.1055/a-2117-4614","url":null,"abstract":"<p>For more than 50 years, light transmission aggregometry has been accepted as the gold standard test for diagnosing inherited platelet disorders in platelet-rich plasma, although there are other functional approaches performed in whole blood. In this article, several advantages and disadvantages of this technique over other laboratory approaches are discussed in the view of recent guidelines, and the necessity of functional assays, such as light transmission aggregometry in the era of molecular genetic testing, is highlighted.</p> ","PeriodicalId":501645,"journal":{"name":"Hämostaseologie","volume":"141 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138564210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}